February 26, 2026 4:53pm

Strength as mid-day re- evolves with a come-back session, as I wrote this a.m., “Sentiment is fragile …; it’s about holding or taking what from which to the bank or the toilet”

From Wednesday, ““Uncle algo and his electronic trading dwarfs” are lurking smelling some profiteering”

News: UniQure NV (QURE) stock plummeted -$7.70 or -31.04% to $17.11 after FDA’s Marty Makary appeared on CNBC to defend the FDA's recent rejections of rare disease drugs.

Pre-open Indication Results: 4 Hits and 2 Miss

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

Thursday’s RMi Pre-opening: Sentiment is fragile … https://www.regmedinvestors.com/articles/14329

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Thursday: The Dow closed UP +17.05 points or +0.03%, the S&P closed DOWN -37.27 points or -0.54% while the Nasdaq closed DOWN -273.694 points or -1.18%

  • Theme of the session: Nvidia (NVDA) set the tone for lower session

Thursday’s (my) 40-company covered sector’s advance/decline line opened negative with 10 incliners, 28 decliners and 2 flats, ending with a positive close of 24 incliners, 14 decliners and 2 flats

  • Back from depths, a re-calibrate

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Initial unemployment claims edged higher last week. 1st-time filings for benefits totaled a seasonally adjusted 212,000 for the week ending Feb. 21, up 4,000 from the previous week’s upwardly revised total but below the consensus estimate for 215,000. On a longer-term basis, the 4-week moving average rose by just 750 to 220,250. Continuing claims, which run a week behind, dropped by 31,000 to 1.833 M.

The CBOE Fear (VIX) index, Thursday closed at 18.62, after Wednesday’s 17.89, Tuesday’s 19.61, Monday’s 21.01, Friday’s 19.11 and Thursday’s 20.28

Metrics: Thursday …

  • The RUT was up +13.96 points or +0.52%,
  • The XLV was down -0.41 points or -0.26%,
  • The NBI was down -42,65 points or -0.71%;
  • The XBI was down -0.61 points or -0.48%
  • The IWM was up +1.39 or +0.53%;
  • The IBB was down -1.42 points or -0.81%,
  • The VIX was up +0.69 points or +3.85% at to 18.62

 

Q1/26 February – 1 holiday, 7 negative and 11 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Thursday Closing UP (10 of 24) 

  • IQIA Holdings (IQV +$8.66 after Wednesday’s -$3.80 after Tuesday’s +$2.56 after Monday’s -$3.51 after Friday’s -$3.67),
  • CRISPR Therapeutics (CRSP +$6.54 after Wednesday’s -$1.57 after Tuesday’s +$2.79 after Monday’s +$0.52 after Friday’s -$1.18),
  • Alnylam Pharmaceuticals (ALNY +$4.10 after Wednesday’s -$5.71 after Tuesday’s +$3.50 after Monday’s -$6.84),
  • Arrowhead Pharmaceuticals (ARWR +$1.77 after Wednesday’s -$2.05),
  • Intellia Therapeutics (NTLA +$0.86),
  • Wave Life Sciences (WVE +$0.82 after Wednesday’s +$0.52),
  • Entrada Therapeutics (TRDA +$0.81 after Wednesday’s +$0.50),
  • AxoGen (AXGN +$0.68 after Wednesday’s -$1.28 after Tuesday’s -$2.88),
  • Vericel VCEL +$0.59 after Wednesday’s -$1.16 after Tuesday’s $0.00),
  • Moderna (MRNA +$0.34 after Wednesday’s +$0.85),

Flat (3)

  • Dyne Therapeutics (DYN)
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Generation Bio (GBIO) – acquired

Thursday’s Closing DOWN (14 of 14): 

  • Vertex (VRTX -$2.70 after Wednesday’s -$4.60 after Tuesday’s +$6.42 after Monday’s +$4.11),
  • uniQure NV (QURE -$7.70 after Wednesday’s +$0.79 after Tuesday’s -$0.43 after Monday’s +$1.03),
  • Sarepta Therapeutics (SUPN -$1.52),
  • BioNTech (BNTX -$1.04 after Wednesday’s -$1.05 after Tuesday’s +$0.96 after Monday’s -$0.21),
  • Beam Therapeutics (BEAM -$0.69 after Wednesday’s -$2.68 after Tuesday’s +$3.96 after Monday’s +$0.74),
  • Supernus Therapeutics (SUPN -$0.57 after Wednesday’s +$3.02 after Tuesday’s +$2.61 after Monday’s -$0.17),
  • Capricor Therapeutics (CAPR -$0.46 after Wednesday’s +$0.44),
  • MiMedx (MDXG -$0.34),
  • Ionis Pharmaceuticals (IONS -$0.33 after Wednesday’s -$4.52 after Tuesday’s +$0.85 after Monday’s +$1.45),
  • Cellectis SA (CLLS -$0.165),
  • Compass Therapeutics (CMPX -$0.11),
  • Sangamo Therapeutics (SGMO -0.03),
  • Precigen (-$0.03),
  • Solid Biosciences (SLDB -$0.02),

 

The Bottom Line: More of the … WHY

From the depths of sold to a rebound on Thursday, the cell and gerne therapy sector (C&GT) beat the odds!

  • The Dow was back to a sort-of “breakeven” on Thursday as the index looked to overcome Nvidia’s (NVDA) sharp decline after earnings. The Nvidia, down -1.2% after earnings, shaved points from the Dow.

 

More earnings this week and coming… Earnings release dates: soon to be catching up

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Rocket pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 4th week

  • 2/26 – Thursday closed positive with 24 incliners, 14 decliners and 2 flats
  • 2/25 -Wednesday closed positive with 20 incliners, 19 decliners and 1 flat
  • 2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats
  • 2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

February – 3rd week

  • 2/20 - Friday closed negative with 13 incliners, 26 decliners and 1 flat
  • 2/19 – Thursday closed positive with 25 incliners, 12 decliners and 3 flats
  • 2/18 - Wednesday closed positive with 30 incliners, 8 decliners and 2 flats
  • 2/17 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 2/16 – Monday was market holiday

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Thursday: IQIA Holdings (IQV), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY)
  • Wednesday: Supernus Therapeutics (SUPN), Moderna (MRNA) and uniQure NV (QURE)
  • Tuesday: Vertex (VRTX), Beam Therapeutics (BEAM) and Alnylam Pharmaceuticals (ALNY)  
  • Monday: Vertex (VRTX), Ionis Pharmaceuticals (IONS) and uniQure NV (QURE)

The worst three (3) in the session: Losers

  • Thursday: uniQure NV (QURE), Vertex (VRTX) and Sarepta Therapeutics (SRPT)
  • Wednesday: Ionis Pharmaceuticals (IONS), Vertex (VRTX) and Alnylam Pharmaceuticals (ALNY)
  • Tuesday: AxoGen (AXGN), uniQure NV (QURE), and BioLife Solutions (BLFS)
  • Monday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Sarepta Therapeutics (SRPT)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.